[PDF][PDF] Complementary role of vitamin D deficiency and the interleukin‐28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C
D Bitetto, G Fattovich, C Fabris, E Ceriani, E Falleti… - …, 2011 - Wiley Online Library
The widely accepted interleukin‐28B (IL‐28B) rs12979860 C/T polymorphism and the more
recently proposed vitamin D serum concentration are two novel predictors of the response to …
recently proposed vitamin D serum concentration are two novel predictors of the response to …
[PDF][PDF] Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C
E Falleti, D Bitetto, C Fabris, G Fattovich… - …, 2012 - Wiley Online Library
Vitamin D deficiency seems to predict the unsuccessful achievement of sustained viral
response (SVR) after antiviral treatment in hepatitis C virus (HCV) difficult‐to‐treat …
response (SVR) after antiviral treatment in hepatitis C virus (HCV) difficult‐to‐treat …
Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals?
LA Kondili, S Robbins, S Blach, I Gamkrelidze… - Liver …, 2018 - Wiley Online Library
Abstract Background & Aims Advances in direct‐acting antiviral treatment of HCV have
reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated …
reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated …
[HTML][HTML] Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the …
LA Kondili, GB Gaeta, MR Brunetto, A Di Leo… - PLoS …, 2017 - journals.plos.org
Background Few data are available on the virological and clinical outcomes of advanced
liver disease patients retreated after first-line DAA failure. Aim To evaluate DAA failure …
liver disease patients retreated after first-line DAA failure. Aim To evaluate DAA failure …
[PDF][PDF] Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort
LA Kondili, F Romano, FR Rolli, M Ruggeri… - …, 2017 - Wiley Online Library
We evaluated the cost‐effectiveness of two alternative direct‐acting antiviral (DAA) treatment
policies in a real‐life cohort of hepatitis C virus–infected patients: policy 1,“universal,” treat …
policies in a real‐life cohort of hepatitis C virus–infected patients: policy 1,“universal,” treat …
[HTML][HTML] Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the …
LA Kondili, GB Gaeta, D Ieluzzi, AL Zignego, M Monti… - PLoS …, 2017 - journals.plos.org
Background There are few real-life data on the potential drug-drug interactions (DDIs)
between anti-HCV direct-acting antivirals (DAAs) and the comedications used. Aim To …
between anti-HCV direct-acting antivirals (DAAs) and the comedications used. Aim To …
[PDF][PDF] A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort
LA Kondili, M Monti, MG Quaranta, L Gragnani… - …, 2022 - Wiley Online Library
Abstract Background and Aims Mixed cryoglobulinemia is the most common HCV
extrahepatic manifestation. We aimed to prospectively evaluate the cryoglobulinemic …
extrahepatic manifestation. We aimed to prospectively evaluate the cryoglobulinemic …
Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy
D Ieluzzi, L Covolo, F Donato, G Fattovich - Digestive and Liver Disease, 2014 - Elsevier
Background The natural history of chronic hepatitis B is variable. We evaluated some of the
risk factors for cirrhosis, hepatocellular carcinoma and liver-related mortality in Italian …
risk factors for cirrhosis, hepatocellular carcinoma and liver-related mortality in Italian …
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and …
Objective Reliable tools to predict long-term outcome among patients with well
compensated advanced liver disease due to chronic HCV infection are lacking. Design Risk …
compensated advanced liver disease due to chronic HCV infection are lacking. Design Risk …
[HTML][HTML] Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort
LA Kondili, MG Quaranta, L Cavalletto… - Digestive and Liver …, 2023 - Elsevier
Background and aims Severe liver disease markers assessed before HCV eradication are
acknowledged to usually improve after the SVR. We prospectively evaluated, in the PITER …
acknowledged to usually improve after the SVR. We prospectively evaluated, in the PITER …